Latest Breaking News On - Gain therapeutics inc - Page 14 : comparemela.com

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International Congress of Parkinson’s Disease and Movement Disorders® in Copenhagen, Denmark BETHESDA, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today annou

Matthias alderSusan sharpeLinnden communicationsGain therapeutics incMovement disordersHuman research ethics committeeInternational congressExchange commissionCompany annual report on formExchange commission onChief executive officerLate breaker abstractMonths ended juneGain therapeuticsPrivate securities litigation reform actAnnual report

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson s Disease and Movement Disorders®

BETHESDA, Md., Aug. 07, 2023 Gain Therapeutics, Inc., , a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today.

Susan sharpeMatthias alderJoanne taylorInternational congressGain therapeutics incMovement disordersResearch at gainLinnden communicationsLate breaker abstractSenior vice presidentGain therapeutics

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson s Disease and Movement Disorders

07.08.2023 - BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) - Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a late .

Matthias alderJoanne taylorSusan sharpeGain therapeutics incLinnden communicationsResearch at gainLate breaker abstractSenior vice presidentGain therapeutics

Gain Therapeutics, Inc (NASDAQ:GANX) Sees Large Decrease in Short Interest

Gain Therapeutics, Inc (NASDAQ:GANX) Sees Large Decrease in Short Interest
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Renaissance technologiesNewedge advisorsDimensional fund advisorsGain therapeutics incRoyal bankGain therapeuticsGet free reportStreet groupFund advisorsSite directed enzyme enhancement therapyGain therapeutics daily

Gain Therapeutics, Inc (NASDAQ:GANX) Expected to Post Q4 2023 Earnings of ($0 28) Per Share

Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) – HC Wainwright lifted their Q4 2023 EPS estimates for Gain Therapeutics in a research report issued to clients and investors on Monday, May 15th. HC Wainwright analyst B. Pachaiyappan now anticipates that the company will earn ($0.28) per share for the quarter, up from their previous estimate […]

Renaissance technologiesSusquehanna international groupRoyal bankGain therapeutics incRaymond james associatesDimensional fund advisorsGain therapeuticsGet ratingGain therapeuticChardan capitalInternational groupSite directed enzyme enhancement therapyGain therapeutics dailyNasdaq ganxEarnings estimatesHc wainwright